Results 271 to 280 of about 704,542 (298)

Assessing Early Postoperative Benefits of a Nerve Block: Methodology Is Important

The Annals of Thoracic Surgery, 2022
Xin Luo, Fu-Shan Xue, Cheng-Wen Li
openaire   +2 more sources

Health Care Data in Early Benefit Assessment – What data is suitable?

2014
Background: In Germany newly authorized pharmaceuticals have to undergo the procedure of the early benefit assessment since 2011. The assessment focuses on patient benefits and the findings of the early assessment to form the basis for subsequent price negotiations. The assessment is solely based on[for full text, please go to the a.m. URL]
openaire   +1 more source

Risk-benefit assessment of nutritional immune interventions during early life

Allergy: European Journal of Allergy and Clinical Immunology, 2016
Background: The immune health status is strongly determined during early life stages. Many immune-related diseases are thought to find their origin in adverse shifts in immune balances during pregnancy or the first 2-3 years of life, including atopic diseases.
Van Bilsen, J., Krul, L., Kuper, F., Wolterbeek, A., Rouhani Rankouhi, T., Verschuren, L., Cnossen, H., Jeurink, P., Garssen, J., Knippels, L., Garthoff, J., Houben, G., Leeman, W.   +12 more
openaire   +1 more source

[Interplay between marketing authorization and early benefit assessment of drugs].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2017
The early benefit assessment of newly approved drugs with new active substances or new applications that came into force on 1 January 2011 still presents a challenge to the parties involved. This article highlights the interplay between drug marketing approval and early benefit assessment.
Peggy, Beinlich, J, Müller-Berghaus, T, Sudhop, S, Vieths, K, Broich   +4 more
openaire   +1 more source

[Assessing the added benefit of new ophthalmic drugs : Which additional insights can be extracted from the early benefit assessment?]

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2019
Until now six ophthalmic agents have undergone the German early benefit assessment according to § 35a Social Security Code (SGB) V in a total of eleven indications. Only one agent (ocriplasmin) was recognized by the Federal Joint Committee as having an added benefit based on submitted study data for a subpopulation (indication of a considerable added ...
M, Appelrath, G, Glaeske
openaire   +1 more source

Results of early benefit assessment (AMNOG) and additional treatment costs: is there a relationship?

2014
Background: Total expenditures for pharmaceuticals in Germany in 2012 added up to approx. 43 billion euros [ref:1] with a considerably increasing share of patented drugs during the last 20 years [ref:2]. Since 2011 an early benefit assessment in accordance with the AMNOG legislation[for full text, please go to the a.m. URL]
Herr, D, Thürmann, PA
openaire   +2 more sources

A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?

Expert Review of Pharmacoeconomics and Outcomes Research, 2022
Charalabos-Markos Dintsios
exaly  

An unconditional prenatal cash benefit is associated with improved birth and early childhood outcomes for Metis families in Manitoba, Canada

Children and Youth Services Review, 2021
Shannon Struck, Jennifer E Enns, Julianne Sanguins   +2 more
exaly  

Primary Endpoint Setting When Assessing Early Postoperative Benefits of a Nerve Block

The Annals of Thoracic Surgery, 2022
openaire   +2 more sources

HTA122 Health-Related Quality of Life in the German Early Benefit Assessment

Value in Health, 2022
M Barth, L Kramer, B Thaa, M Moos, M Esser   +4 more
openaire   +1 more source